PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26056458-4 2015 The use of subcutaneous polyethylene glycol (PEG)ylated interferon beta-1a (PEG-IFN) has been proposed to offer a better combination of pharmacokinetic and pharmacodynamic profiles and therapy-related side effects. Polyethylene Glycols 24-43 interferon beta 1 Homo sapiens 56-71 28752785-1 2018 We report the case of a 42-year-old female patient who developed peculiar skin lesions due to subcutaneous polyethylene glycol (PEG) interferon beta-1a. Polyethylene Glycols 107-126 interferon beta 1 Homo sapiens 133-148 28752785-1 2018 We report the case of a 42-year-old female patient who developed peculiar skin lesions due to subcutaneous polyethylene glycol (PEG) interferon beta-1a. Polyethylene Glycols 128-131 interferon beta 1 Homo sapiens 133-148 29484976-8 2018 Less frequent dosing and improved pharmacological properties have been achieved by reaction of interferon beta with chemically activated polyethylene glycol. Polyethylene Glycols 137-156 interferon beta 1 Homo sapiens 95-110 28129467-3 2017 In the present study, we report on the development of a novel, engineered form of human and murine IFN-beta, each conjugated with a polyethylene glycol molecule (PEG-hIFN-beta and PEG-mIFN-beta, respectively). Polyethylene Glycols 132-151 interferon beta 1 Homo sapiens 166-175 30050377-6 2017 Pegylation, the process by which molecules of polyethylene glycol are covalently linked to a compound, has been utilized to increase the half-life of IFNbeta and decrease the frequency of administration required. Polyethylene Glycols 46-65 interferon beta 1 Homo sapiens 150-157 27800024-1 2016 Peginterferon beta1a is a modified form of interferon beta1a with a polyethylene glycol (PEG) group attached to the alpha-amino group of the N terminus of the interferon molecule. Polyethylene Glycols 68-87 interferon beta 1 Homo sapiens 3-19 27800024-1 2016 Peginterferon beta1a is a modified form of interferon beta1a with a polyethylene glycol (PEG) group attached to the alpha-amino group of the N terminus of the interferon molecule. Polyethylene Glycols 89-92 interferon beta 1 Homo sapiens 3-19 21680782-2 2012 Two randomized, blinded phase I studies were conducted: a single-dose study (n = 60) comparing subcutaneous or intramuscular PEG-IFN beta-1a (63, 125, or 188 microg) with intramuscular unmodified IFN beta-1a 30 microg and a multiple-dose study (n = 69) comparing subcutaneous PEG-IFN beta-1a dosed once every 2 or 4 weeks with placebo. Polyethylene Glycols 125-128 interferon beta 1 Homo sapiens 129-137 23962003-3 2013 Covalent modification of IFN-beta with polyethylene glycol (PEG) improves the pharmacokinetic properties of the protein, but can adversely affect the protein"s in vitro bioactivity. Polyethylene Glycols 39-58 interferon beta 1 Homo sapiens 25-33 25666445-1 2015 Peginterferon beta-1a (Plegridy ), an interferon beta-1a conjugated to a methoxy polyethylene glycol (PEG) molecule, is available in the EU and the USA for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS). Polyethylene Glycols 102-105 interferon beta 1 Homo sapiens 3-18 23962003-3 2013 Covalent modification of IFN-beta with polyethylene glycol (PEG) improves the pharmacokinetic properties of the protein, but can adversely affect the protein"s in vitro bioactivity. Polyethylene Glycols 60-63 interferon beta 1 Homo sapiens 25-33 23962003-4 2013 Random modification of lysine residues in IFN-beta with amine-reactive PEGs decreased the in vitro bioactivity of the protein 50-fold, presumably due to modification of lysine residues near critical receptor binding sites. Polyethylene Glycols 71-75 interferon beta 1 Homo sapiens 42-50 23962003-5 2013 PEGylated IFN-beta proteins that retained high in vitro bioactivity could be obtained by selective modification of the N-terminus of the protein with PEG. Polyethylene Glycols 0-3 interferon beta 1 Homo sapiens 10-18 23962003-6 2013 Here we use site-specific PEGylation technology (targeted attachment of a cysteine-reactive-PEG to an engineered cysteine residue in IFN-beta) to identify several additional amino acid positions where PEG can be attached to IFN-beta without appreciable loss of in vitro bioactivity. Polyethylene Glycols 26-29 interferon beta 1 Homo sapiens 133-141 23962003-6 2013 Here we use site-specific PEGylation technology (targeted attachment of a cysteine-reactive-PEG to an engineered cysteine residue in IFN-beta) to identify several additional amino acid positions where PEG can be attached to IFN-beta without appreciable loss of in vitro bioactivity. Polyethylene Glycols 26-29 interferon beta 1 Homo sapiens 224-232 23962003-6 2013 Here we use site-specific PEGylation technology (targeted attachment of a cysteine-reactive-PEG to an engineered cysteine residue in IFN-beta) to identify several additional amino acid positions where PEG can be attached to IFN-beta without appreciable loss of in vitro bioactivity. Polyethylene Glycols 92-95 interferon beta 1 Homo sapiens 133-141 23962003-6 2013 Here we use site-specific PEGylation technology (targeted attachment of a cysteine-reactive-PEG to an engineered cysteine residue in IFN-beta) to identify several additional amino acid positions where PEG can be attached to IFN-beta without appreciable loss of in vitro bioactivity. Polyethylene Glycols 92-95 interferon beta 1 Homo sapiens 224-232 22156480-3 2011 DFPP was used in combination with IFN-beta/RBV with subsequent administration of PEG-IFN-alpha2a/RBV therapy (DFPP + IFN-beta/RBV then PEG-IFN/RBV). Polyethylene Glycols 81-84 interferon beta 1 Homo sapiens 117-125 21690216-2 2011 A 20-kDa polyethylene glycol (PEG)-conjugated IFN beta-1a (PEG-IFN beta-1a) is being developed to decrease the frequency of administration and improve patient convenience and compliance. Polyethylene Glycols 9-28 interferon beta 1 Homo sapiens 46-54 21690216-2 2011 A 20-kDa polyethylene glycol (PEG)-conjugated IFN beta-1a (PEG-IFN beta-1a) is being developed to decrease the frequency of administration and improve patient convenience and compliance. Polyethylene Glycols 9-28 interferon beta 1 Homo sapiens 63-71 21690216-2 2011 A 20-kDa polyethylene glycol (PEG)-conjugated IFN beta-1a (PEG-IFN beta-1a) is being developed to decrease the frequency of administration and improve patient convenience and compliance. Polyethylene Glycols 30-33 interferon beta 1 Homo sapiens 46-54 21690216-2 2011 A 20-kDa polyethylene glycol (PEG)-conjugated IFN beta-1a (PEG-IFN beta-1a) is being developed to decrease the frequency of administration and improve patient convenience and compliance. Polyethylene Glycols 30-33 interferon beta 1 Homo sapiens 63-71 6678936-2 1983 Different derivatives of polyethylene glycol (PEG)--liquid ion exchangers or affinity ligands--can be effectively used for the extraction of IFN-beta in combination with Dextran-T 500 or orthophosphate. Polyethylene Glycols 25-44 interferon beta 1 Homo sapiens 141-149 6678936-2 1983 Different derivatives of polyethylene glycol (PEG)--liquid ion exchangers or affinity ligands--can be effectively used for the extraction of IFN-beta in combination with Dextran-T 500 or orthophosphate. Polyethylene Glycols 46-49 interferon beta 1 Homo sapiens 141-149 2488591-1 1989 Recombinant human interferon-beta (IFN-beta), a highly basic and hydrophobic protein, has been isoelectric focused using the nonionic detergent polyoxyethylene 12 lauryl ether (laureth 12). Polyethylene Glycols 144-159 interferon beta 1 Homo sapiens 18-33 2488591-1 1989 Recombinant human interferon-beta (IFN-beta), a highly basic and hydrophobic protein, has been isoelectric focused using the nonionic detergent polyoxyethylene 12 lauryl ether (laureth 12). Polyethylene Glycols 144-159 interferon beta 1 Homo sapiens 35-43